Skip to main content
SpringerLink
Log in

Hormonrezeptor-positives, HER2‑negatives metastasiertes Mammakarzinom in der Prämenopause: endokrin-basierte Kombinationstherapie ist effektiver als Chemotherapie

Hormone receptor positive, HER2 negative premenopausal metastatic breast cancer—endocrine-based combination treatment is more effective than chemotherapy

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Janni W, Schneeweiss A, Müller V et al (2019) Update breast cancer 2019 part 2—implementation of novel diagnostics and therapeutics in advanced breast cancer patients in clinical practice. Geburtshilfe Frauenheilkd 79:268–280

    Article  Google Scholar 

  2. Banys-Paluchowski M, Krawczyk N, Paluchowski P (2019) Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances. Curr Opin Obstet Gynecol 31:56–66

    Article  Google Scholar 

  3. Sledge GW Jr., Toi M, Neven P et al (2019) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.4782

    Article  PubMed  PubMed Central  Google Scholar 

  4. Im SA, Lu YS, Bardia A et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307–316

    Article  Google Scholar 

  5. Slamon D, Neven P, Chia S et al (2019) Overall survival (OS) results of the phase III MONALEESA‑3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2‑negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann Oncol 30(5):v851–v934. https://doi.org/10.1093/annonc/mdz394

    Article  Google Scholar 

  6. Kommission Mamma (Hrsg) (2019) Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome

    Google Scholar 

  7. Hartkopf AD, Huober J, Volz B et al (2018) Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors—data from the German PRAEGNANT breast cancer registry. Breast 37:42–51

    Article  Google Scholar 

  8. Gomez SL, Yao S, Kushi LH et al (2019) Is breast cancer in Asian and Asian American women a different disease? J Natl Cancer Inst. https://doi.org/10.1093/jnci/djz091

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Asklepios Klinik Hamburg-Barmbek, Rübenkamp 220, 22307, Hamburg, Deutschland

    M. Banys-Paluchowski

Authors
  1. M. Banys-Paluchowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Banys-Paluchowski.

Ethics declarations

Interessenkonflikt

M. Banys-Paluchowski erhielt Honorare für Vorträge und beratende Tätigkeiten von Roche, Pfizer, Novartis und Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Banys-Paluchowski, M. Hormonrezeptor-positives, HER2‑negatives metastasiertes Mammakarzinom in der Prämenopause: endokrin-basierte Kombinationstherapie ist effektiver als Chemotherapie. Onkologe 26, 289–291 (2020). https://doi.org/10.1007/s00761-019-00706-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-019-00706-4

Search

Navigation